文献速递脊柱关节炎

基于HLA-B*27状态的轴性脊柱关节炎临床特征与治疗利用:ASAS-PerSpA研究结果

Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study.
PubMed 文献 · RMD Open · 2023-01-01

该研究为ASAS-PerSpA研究的事后分析,纳入2910例符合2009年ASAS分类标准的轴性脊柱关节炎患者,其中2269例检测了HLA-B*27(1753例阳性、516例阴性)。HLA-B*27阴性患者外周关节炎、附着点炎、银屑病和炎症性肠病比例更高,且更常用csDMARDs;HLA-B*27阴性状态与附着点炎、银屑病和炎症性肠病正相关,与葡萄膜炎负相关。

要点

  • HLA-B*27阴性轴性脊柱关节炎患者外周关节炎、附着点炎、银屑病和炎症性肠病比例更高。
  • HLA-B*27阴性患者csDMARDs暴露更高(61.2% vs 55.0%)。
  • 多变量分析显示HLA-B*27阴性与附着点炎、银屑病和炎症性肠病正相关,与葡萄膜炎负相关。

核心结论

  • HLA-B*27阴性轴性脊柱关节炎患者诊断延迟更长,更常出现外周关节炎、附着点炎、炎症性肠病和银屑病,且更常用csDMARDs。

研究设计与样本

  • ASAS-PerSpA研究的事后分析,纳入符合2009年ASAS分类标准且检测HLA-B*27的轴性脊柱关节炎患者,比较HLA-B*27阳性和阴性亚组特征,并用多变量逻辑回归识别HLA-B*27阴性的预测因素。

主要发现

  • 共纳入来自24个国家的2910例轴性脊柱关节炎患者,其中2269例检测HLA-B*27:1753例阳性、516例阴性。
  • HLA-B*27阳性组男性比例高于阴性组(72.1% vs 54.3%),阳性组家族史比例更高(29.8% vs 15.3%),诊断年龄更轻(31.6岁 vs 37.7岁)。
  • HLA-B*27阴性组外周关节炎(47.5% vs 42.1%,p<0.05)、银屑病(19.4% vs 10.2%)、附着点炎(56.6% vs 49.8%)和炎症性肠病(12.8% vs 3.4%)比例显著更高(p<0.001)。
  • HLA-B*27阴性组csDMARDs暴露更高(61.2% vs 55.0%,p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to characterize differences of clinical features, extra-musculoskeletal manifestations and treatment utilizations based on the patients' HLA-B*27 status in a global axSpA cohort and identify predictors of HLA-B*27 negativity in these patients. METHODOLOGY: In post-hoc analysis of the ASAS-PerSpA study, patients fulfilling the 2009 ASAS classification criteria for axSpA and typed for HLA-B*27 were included. The patient characteristics cwere compared between the HLA-B*27(+) and HLA-B*27(-) subgroups. Multivariablete logistic regression was conducted to identify predictors of HLA-B*27 negativity. RESULTS: Of 2910 patients with axSpA from 24 countries, 2269 were tested for HLA-B*27 [1753 HLA-B*27(+) and 516 HLA-B*27(-)]. The proportion of males was higher in the HLA-B*27 (+) compared to the HLA-B*27 (-) subgroup (72.1 vs 54.3%). Patient population with HLA-B*27 (+) more often had positive family history for axSpA (29.8 vs 15.3%), and younger age at diagnosis, 31.6 years (SD 10.9) vs 37.7 years (SD 12.1). HLA-B*27 (-) patients had significantly higher peripheral arthritis (47.5 vs 42.1%, p<0.05), psoriasis (19.4 vs 10.2), enthesitis (56.6 vs 49.8%) and IBD (12.8 vs 3.4) (p<0.001). The exposure to csDMARDS in HLA-B*27 (-) patients was higher (61.2 vs 55.0%, p< 0.05). On multivariable analysis, HLA-B*27 (-) status was positively associated with enthesitis, psoriasis and IBD with an OR 1.27 (1.02-1.57), 1.84 (1.36-2.48) and 4.84 (3.23-7.30) respectively, and inversely associated with uveitis, OR 0.37 (0.27-0.50). CONCLUSION: HLA-B*27 (-) axSpA patients had a longer delay in diagnosis, more frequently had peripheral arthritis, enthesitis, IBD, psoriasis, and were more often treated with csDMARDs compared to HLA-B*27 (+) subgroup.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Chaudhary H, López-Medina C, Khan MA, et al. Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study. RMD Open. 2023. PMID: 37491128. doi:10.1136/rmdopen-2023-003179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。